Prevalence of pancreatic, hepatic and renal microscopic lesions in post-mortem samples from cavalier King Charles spaniels by Kent, A.C.C. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prevalence of pancreatic, hepatic and renal microscopic lesions
in post-mortem samples from cavalier King Charles spaniels
Citation for published version:
Kent, ACC, Constantino-Casas, F, Rusbridge, C, Corcoran, B, Carter, M, Ledger, T & Watson, PJ 2016,
'Prevalence of pancreatic, hepatic and renal microscopic lesions in post-mortem samples from cavalier King
Charles spaniels' Journal of Small Animal Practice, vol. 57, no. 4, pp. 188-193. DOI: 10.1111/jsap.12444
Digital Object Identifier (DOI):
10.1111/jsap.12444
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Small Animal Practice
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
  1 
Original Article 1 
 2 
Prevalence of pancreatic, hepatic and renal pathology in post-mortem samples from 3 
Cavalier King Charles Spaniels presented to a collection scheme 4 
 5 
A.C.C. Kent a, *, F. Constantino-Casas a, C. Rusbridge b, B.M. Corcoran c, M. Carter d, 6 
T. Ledger d, P.J. Watson a 7 
 8 
a Department of Veterinary Medicine, University of Cambridge, Madingley Road, 9 
Cambridge. United Kingdom. CB3 0ES 10 
b Fitzpatrick Referrals, Halfway Lane, Eashing, Godalming, Surrey. GU7 2QQ 11 
c University of Edinburgh, Hospital for Small Animals, Easter Bush Veterinary 12 
Centre, Roslin, Midlothian. EH25 9RG 13 
d The Cavalier Collection Scheme, 47 The Ryde, Hatfield. AL9 5DQ. 14 
 15 
 16 
 17 
 18 
 19 
* Corresponding author. Tel: +44 1223 337621 20 
   Email address: ack44@cam.ac.uk (A.C.C. Kent) 21 
 22 
  23 
  2 
Abstract 24 
The Cavalier King Charles Spaniel is a common breed in the UK. Chronic valvular 25 
disease and syringohydromyelia are frequently reported in this breed but there is less 26 
information on other diseases despite a suspicion of over-representation. 27 
 28 
The goal of this study was to describe the prevalence of pancreatic, hepatic and renal 29 
pathology in Cavalier King Charles Spaniels presented to a pathology collection 30 
scheme in the UK and to relate these back to the clinical signs shown during their 31 
lifetime by evaluation of their clinical history. 32 
 33 
54 dogs were available for analysis, ranging from 3 to 16 years of age and from 6 to 34 
15.7 Kg in weight. The cause of death was most commonly congestive heart failure, 35 
syringohydromyelia or other neurological disorders. 36 
 37 
Evidence of chronic pancreatitis was seen in 51.9% of the cases, the age of dogs with 38 
mild chronic pancreatitis was significantly lower than those dogs with more severe 39 
disease. Evidence of renal pathology was present in 52.2% of cases, most commonly 40 
inflammatory disease. The rate of ante-mortem diagnosis was low for both pancreatic 41 
and renal disease, at 25% and 16.7% respectively. 42 
 43 
Pancreatic and renal pathology are common in Cavalier King Charles Spaniels and 44 
clinicians should be aware of this when presented with clinical cases. 45 
 46 
Keywords: Chronic pancreatitis; Cavalier King Charles Spaniel; Renal; Hepatic; 47 
Pathology  48 
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Introduction 49 
The Cavalier King Charles Spaniel (CKCS) is a common breed in the United 50 
Kingdom. The breed is commonly reported to suffer from chronic mitral valve disease 51 
(Beardow et al., 1993) and syringohydromyelia (Rusbridge et al., 2000), however less 52 
information exists on other pathologies, such as pancreatic, renal and hepatic disease, 53 
although there is a suspicion of an increased prevalence of chronic pancreatitis in the 54 
breed (Watson et al., 2007).  55 
 56 
The Cavalier collection scheme (http://www.thecavaliercollectionscheme.org) was 57 
initially started by motivated cavalier owners and breeders in collaboration, in order 58 
to obtain post-mortem samples of the central nervous system from CKCS which had 59 
had MRI prior to death to gain a better understanding of syringohydromyelia. It was 60 
then extended to include samples of mitral valve for further studies of chronic 61 
valvular disease. More recently, as increasing recognition of other diseases developed, 62 
the scheme was extended again to include pancreatic, hepatic and renal samples. 63 
 64 
Pancreatic, renal and hepatic diseases can be difficult to diagnose ante-mortem, due to 65 
the non-specific nature of clinical signs, a lack of highly sensitive diagnostic tests and 66 
variable disease progression. They can, however, cause significant morbidity in 67 
affected dogs and so an indication of prevalence would be useful to help guide 68 
clinicians to undertake appropriate diagnostic tests in living animals. 69 
 70 
This study aimed to assess the prevalence of pancreatic, renal and hepatic pathology 71 
in a population of CKCS presented to a post-mortem collection scheme and to relate 72 
these back to the clinical history of those dogs. In addition, the study also aimed to 73 
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assess whether there was any statistically significant association between the different 74 
pathologies. 75 
 76 
Materials and methods 77 
The study aimed to take sections of pancreas, liver and kidney from the dogs 78 
presented to the Cavalier collection scheme by their owners with fully informed 79 
consent, however in a small number of dogs samples were only available for one or 80 
two of these organs. Some of these cases underwent a full post-mortem examination 81 
at the Department of Veterinary Medicine, University of Cambridge (DVMUC) 82 
whilst some cases had samples of the appropriate organs collected by veterinary 83 
surgeons in first-opinion practice in the UK. Full instructions were sent to the 84 
veterinary surgeons to ensure consistent sample collection (appendix 1). CNS samples 85 
were only taken if the dog had a post-mortem examination at DVMUC.  86 
 87 
Each dog also required completion of the submission form for the collection scheme, 88 
which contained questions about relevant medical history. Some cases also had a full 89 
clinical history available.  Medical history required included age and presence or 90 
absence of neurological signs, cardiovascular signs, gastrointestinal signs and any 91 
concurrent diseases (appendix 2 and 3). 92 
 93 
All tissue samples were fixed in 10% neutral buffered formalin solution before being 94 
embedded in paraffin. The paraffin sections (  thick) were then stained with 95 
hematoxylin and eosin. Tissue sections were reviewed by two of the authors (P.J.W. 96 
and F.CC.). 97 
 98 
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Pancreatic pathology was categorised as previously published (Watson et al., 2007). 99 
Chronic pancreatitis was defined as a lymphocytic or mixed inflammatory infiltrate 100 
(lymphocytes, plasma cells, macrophages, neutrophils) with or without fibrosis, with 101 
disruption of the normal pancreatic architecture. All of the pancreas sections were 102 
reviewed by one of the authors (P.J.W.) and allocated to one of the following 103 
categories: 104 
a) No evidence of chronic pancreatitis (Figure 1). 105 
b) Mild chronic pancreatitis: one or two small foci of lymphocytic infiltrate and 106 
fibrosis in the section examined (Figure 2). 107 
c) Moderate chronic pancreatitis: multi-focal areas of fibrosis and lymphocytes 108 
in the section examined but involving less than 50 per cent of area (Figure 3). 109 
d) Marked chronic pancreatitis: multi-focal areas of marked fibrosis and 110 
lymphocytic inflammation producing gross distortion of the normal 111 
architecture with less than 50 per cent of normal tissue remaining (Figure 4). 112 
e) “End-stage” was regarded as virtually no normal acinar tissue remaining 113 
(Figure 5). 114 
 115 
The liver pathology was assessed according to the WSAVA standards for liver 116 
histopathology (ROTHUIZEN, 2006) and allocated to one of the following 117 
categories: 118 
a) No evidence of hepatic disease. 119 
b) Primary hepatic disease. 120 
I. Chronic hepatitis: hepatocellular apoptosis or necrosis with an 121 
inflammatory infiltrate (mononuclear or mixed) and varying degrees of 122 
fibrosis. 123 
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II. Acute hepatitis: a combination of acute inflammation, hepatocellular 124 
apoptosis and necrosis, which may be accompanied by regeneration. 125 
III. Neoplasia. 126 
c) Secondary hepatic disease 127 
I. Hepatic congestion: engorgement and dilation of the hepatic veins and 128 
centrilobular sinusoids, which may be accompanied by dilated 129 
lymphatics and centrilobular perivenular fibrosis. 130 
II. Hepatic vacuolation: hydropic change or fatty change (Figure 6). 131 
III. Reactive hepatitis: inflammatory infiltrate in the portal areas or 132 
parenchyma with no hepatocellular necrosis. 133 
 134 
Renal pathology was assessed into the following categories (Macdougall et al., 1986): 135 
a) Normal 136 
b) Inflammatory disease 137 
I. Glomerulonephritis: proliferation of the endothelial and epithelial cells 138 
of the glomerular capillary with thickening of the glomerular basement 139 
membrane. 140 
II. Interstitial Nephritis: a mixed inflammatory infiltrate of the 141 
interstitium 142 
c) Other pathology 143 
 144 
Dogs were excluded if neither a complete clinical history nor a complete submission 145 
form was available. Some cases did not have samples available from each organ. 146 
 147 
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Dogs were considered to have had clinical signs that may have been consistent with 148 
chronic pancreatitis if they had frequently reported episodes of gastrointestinal signs 149 
(vomiting, diarrhoea, inappetence) or abdominal pain (Watson, 2012). A clinical 150 
diagnosis of renal disease was based on the identification of azotaemia, in the face of 151 
poorly concentrated urine (Lees, 2004). 152 
 153 
Prevalence of pathology was calculated for each organ and compared to the 154 
prevalence of clinical signs. The signalment of dogs with or without pathology was 155 
compared by means of a Mann Whitney U test, the results were considered significant 156 
if p < 0.05. Relative risk was calculated for having renal disease together with chronic 157 
pancreatitis. It was considered significantly increased only if the risk and 95% 158 
confidence interval were greater than 1. Dogs with and without pancreatic pathology 159 
were compared for any significant differences in signalment. 160 
 161 
Results 162 
59 dogs were initially included in the study, 5 were subsequently excluded due to 163 
unavailable histopathology (2 dogs) or unavailable clinical history (3 dogs), leaving 164 
54 dogs for analysis. 165 
 166 
The dogs ranged from 3 to 16 years (mean 10.4 years, median 10.9 years) and from 6 167 
to 15.7Kg in weight (mean 9.3Kg, median 9.3Kg). Dogs were euthanased or died for 168 
a number of reasons, including congestive heart failure (15 dogs), 169 
syringohydromyelia (10 dogs), other neurological disorders (11 dogs, most commonly 170 
degenerative myelopathy or seizures), neoplasia (6 dogs), renal disease (3 dogs), old 171 
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age (3 dogs), liver disease (2 dogs), pancreatic disease (2 dogs), and 1 each of severe 172 
anaemia and aggression. 173 
 174 
18 dogs underwent a full post-mortem examination, the remainder had the relevant 175 
organs sampled by veterinary surgeons in practice. 12 dogs also had histopathology 176 
performed on the central nervous system, these have been reported as part of a 177 
previous study (Hu et al., 2012). 178 
 179 
24 dogs (44.4%) were being treated for cardiac disease at the time of death with a 180 
number of medications including one or more of the following list: frusemide, 181 
pimobendan, spironolactone, benazepril, torsemide and digoxin.  25 dogs had an ante-182 
mortem diagnosis of syringohydromyelia, some of which were receiving medical 183 
therapy including one or more of the following drugs: frusemide, gabapentin, 184 
prednisolone, non-steroidal anti-inflammatory drugs. 185 
 186 
Pancreatic pathology was available for 54 dogs. 28 dogs (51.9%) had evidence of 187 
chronic pancreatitis, which was graded as mild in 10 dogs (35.7%), moderate in 13 188 
dogs (46.4%), marked in 2 dogs (7.1%) and end-stage in 3 dogs (10.7%). 189 
 190 
The median age of dogs with chronic pancreatitis was 11.1 years (range of 4 to 16 191 
years) and without chronic pancreatitis was 9.7 years (range of 3 to 15 years), there 192 
was not a statistically significant difference (p = 0.037). The median weight of dogs 193 
with chronic pancreatitis was 9.75Kg (range of 6 to 13 Kg) and without chronic 194 
pancreatitis was 8.6Kg (range of 6.5 to 15.7 Kg), again there was no significant 195 
difference (p = 0.407). 196 
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 197 
When the age of dogs with mild chronic pancreatitis (n= 10, median 9.75 years) was 198 
compared to a combined group of moderate, marked and end-stage chronic 199 
pancreatitis (n= 18, median 13.0 years) there was a significant difference (p = 0.011). 200 
 201 
Of the 28 dogs with evidence of chronic pancreatitis, only 13 (46.4%) were reported 202 
to have clinical signs consistent with the disease prior to death and only 7 dogs were 203 
diagnosed with chronic pancreatitis ante-mortem. In addition to these findings, one 204 
dog without chronic pancreatitis had nodular hyperplasia and one dog with chronic 205 
pancreatitis also had evidence of superimposed acute pancreatitis and pancreatic 206 
necrosis. 207 
 208 
Renal pathology was available for 46 dogs. 24 dogs (52.2%) had evidence of 209 
abnormal pathology, most commonly glomerulonephritis (9 dogs) or interstitial 210 
nephritis (10 dogs). Other abnormalities included tubular necrosis (1 dog), congestion 211 
(1 dog), the presence of cysts (2 dogs) and steatosis (1 dog). Only 4 dogs (16.7%) had 212 
a diagnosis of renal disease ante-mortem. The median age of the dogs with renal 213 
disease was 12.0 years (range 3.0 to 16.0 years) and without renal disease was 10.25 214 
years (range 4.0 to 15.5 years), this was not a statistically significant difference 215 
(p=0.092).  216 
 217 
Liver histopathology results were available for 54 dogs, this was most commonly 218 
secondary pathology including congestion (12 cases), hepatocyte vacuolation (14 219 
cases), hepatocyte vacuolation and congestion (8 cases), or reactive hepatitis (1 case). 220 
Primary liver pathology was only identified in 6 cases and consisted of fibrosis (2 221 
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cases), cirrhosis (1 case) and chronic hepatitis (3 cases). One case had nodular 222 
hyperplasia. Two of the four dogs with chronic hepatitis and cirrhosis had an ante-223 
mortem diagnosis of liver disease: one dog with cirrhosis and one dog with chronic 224 
hepatitis. 225 
 226 
When considering inflammatory diseases, 8 dogs had both chronic pancreatitis and 227 
renal disease, 3 dogs had chronic pancreatitis and inflammatory liver disease and 1 228 
dog had chronic pancreatitis, renal disease and inflammatory liver disease.  229 
 230 
There was no increase in the relative risk of glomerulonephritis or interstitial nephritis 231 
in dogs with chronic pancreatitis (relative risk 0.8250, 95% CI 0.414 to 1.645, p = 232 
0.58). There was also no increased risk of vacuolar hepatopathy in dogs with chronic 233 
pancreatitis (relative risk 0.6845, 95% CI 0.364 to 1.289, p=0.24). There was no 234 
increased relative risk of hepatic congestion in dogs with cardiac disease (relative risk 235 
0.9900, 95% CI 0.508 to 1.928, p=0.976). Whilst the relative risk of inflammatory 236 
kidney disease was increased in dogs with cardiac disease (relative risk 1.3228, 95% 237 
CI 0.664 to 2.634, p=0.43), the confidence interval falls below 1 so it is unclear how 238 
significant the association is. 239 
 240 
Discussion 241 
This is the first study to examine the prevalence of histopathologically confirmed 242 
pancreatitis, renal and liver disease in a large population of CKCS examined at post-243 
mortem. Whilst the prevalence of pancreatitis has been examined in previous studies 244 
(Newman et al., 2004, Watson et al., 2007), this is the first study to focus on only one 245 
breed of dog. This study shows the prevalence of chronic pancreatitis in the CKCS is 246 
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51.9%, which is greater than the 34% reported in a large study looking at post-247 
mortem samples from a variety of different breeds (Watson et al., 2007). That study 248 
included 6 CKCS, all of which had evidence of chronic pancreatitis. The prevalence 249 
of renal disease was also very high in this study at 52.2% and yet the proportion of 250 
dogs which had ante-mortem diagnosis of either chronic pancreatitis or renal disease 251 
was very small.  252 
 253 
Chronic pancreatitis is suspected to be an under-diagnosed disease, mainly due to the 254 
vague nature of the clinical signs (Watson, 2004) and that is supported by the results 255 
of this study. We found that only 24% of the cases with histological evidence of 256 
chronic pancreatitis had been diagnosed ante-mortem. This may be because the 257 
clinical signs were very intermittent, interpreted to represent an alternative disease or 258 
because the clinical signs were genuinely so subtle. However, chronic pancreatitis is 259 
known to be an important cause of chronic pain in dogs (Watson et al., 2010a, 260 
Bostrom et al., 2013) and in humans (Bouwense et al., 2013). The pain in humans 261 
results in a significant upregulation of central nociception, which is more marked the 262 
more severe the disease (Bouwense et al., 2013). It is possible that cavaliers with 263 
chronic pancreatitis suffer from chronic pain, which may be over-looked or confused 264 
in some cases with the pain of syringomyelia.  It is therefore important for veterinary 265 
practitioners to be aware of chronic pancreatitis in cavaliers and to institute 266 
appropriate management including analgesics with the aim of reducing the morbidity. 267 
 268 
The median age of dogs with more severe disease was greater than dogs with mild 269 
disease. This suggests that chronic pancreatitis is a progressive disease, which 270 
worsens with age. 271 
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 272 
This is the first study to report the prevalence of renal disease in Cavalier King 273 
Charles Spaniels. Glomerulonephritis or interstitial nephritis was identified in 19 dogs 274 
(41%) in this study, whilst only 4 dogs had an ante-mortem diagnosis of renal disease. 275 
24 dogs (44.4%) in this study had congestive heart failure and were on long-term 276 
medication for cardiac disease and this may mean that subtle changes in renal 277 
function were overlooked. Many of the dogs were on medications that may have had 278 
an impact on renal perfusion, for example angiotensin converting enzyme inhibitors 279 
(ACEi) and diuretics and the assumption may have been that mild azotaemia was due 280 
to reduced renal perfusion or the effects of diuresis. However, the changes identified 281 
on pathology were indicative of primary renal disease in many dogs. It is likely that 282 
the dogs with glomerulonephritis had measurable proteinuria and the dogs with 283 
nephritis had poorly concentrated urine. However, the retrospective nature of these 284 
samples means that we do not have comprehensive information on indicators of renal 285 
function in most dogs. It is very important to increase recognition of chronic renal 286 
disease in CKCS ante-mortem because there is strong evidence that changing dogs on 287 
to a phosphate restricted diet formulated for renal disease can increase life-expectancy 288 
by a factor of 3 (Jacob et al., 2002). However, clinicians also need to be aware that 289 
renal diets generally have elevated fat concentrations, which may be problematic if 290 
the dog also has chronic pancreatitis.  291 
 292 
Hepatic pathology was commonly detected in this study but the majority of cases had 293 
secondary findings likely to be related to other pathology. The finding of congestion 294 
was assumed to be related to chronic heart disease. This was not supported by the 295 
relative risk statistics, but sample size was small. The finding of hepatocyte 296 
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vacuolation is likely to be a secondary reactive change of the liver to a variety of 297 
other diseases. The prevalence of secondary hepatic pathology was very similar to 298 
that reported in a previous study in a number of breeds of dogs (Watson et al., 2010b).  299 
 300 
The authors considered whether an association might exist between the different 301 
pathologies encountered. It was hypothesised that chronic pancreatitis might lead to 302 
an increased risk of glomerulonephritis due to the chronic inflammation and potential 303 
for immune complex deposition. Alternatively it was thought possible that chronic 304 
renal disease might cause pancreatitis, due to alterations in blood flow and an increase 305 
in circulating toxins. However in this study there was no increased risk of 306 
glomerulonephritis or interstitial nephritis in CKCS with chronic pancreatitis. It was 307 
equally considered that vacuolar hepatopathy may occur as a sequel to the chronic 308 
disease of chronic pancreatitis, however we found no evidence of an increased risk in 309 
this study. This agrees with a previous study (Watson et al. 2010b). That study did 310 
identify an increased relative risk of reactive hepatitis in dogs with chronic 311 
pancreatitis (Watson et al., 2010b). Only one dog in the current study was reported 312 
with reactive hepatitis so numbers were too small to investigate any potential 313 
association.  314 
 315 
There are a number of limitations to this study. The first is the retrospective nature of 316 
the study, which meant that the CKCS had been exposed to a number of different 317 
therapeutic regimes ante-mortem, which may have impacted the pathology findings. 318 
The study was also reliant on owners to provide accurate clinical information which 319 
means that some information may have been missing. Investigating pancreatitis is 320 
also inherently difficult, as the pathology is not always uniformly distributed 321 
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throughout the organ. Lastly, the grading of pancreatitis is relatively subjective. 322 
However all of the pancreas sections in this study were reviewed by one person, 323 
which should allow some consistency of interpretation. 324 
 325 
Conclusions 326 
This is the first study to look at the prevalence of pathology of the liver, pancreas and 327 
kidney in the Cavalier King Charles Spaniel and it demonstrates a surprisingly high 328 
prevalence of chronic pancreatitis and renal disease in this breed (51.9% and 52.2% 329 
respectively), most of which were not diagnosed ante-mortem. Clinicians have in the 330 
past focussed on heart disease in the breed but should also be aware of the potential 331 
for these other diseases and consider them when confronted with clinical cases 332 
showing appropriate presenting signs. It is hoped that the results of this study will 333 
increase recognition and appropriate treatment of chronic pancreatitis and chronic 334 
kidney disease in Cavalier King Charles Spaniels, so improving the quality of life of 335 
affected dogs. Studies in the future should focus on understanding the reasons for 336 
these high disease prevalences in the breed.  337 
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Figure legends 392 
 393 
Fig. 1. Normal pancreas from a 10-year-old female CKCS. Most of the section 394 
consists of exocrine adenomeres with multiple pancreatic islets (arrows). H&E, bar: 395 
300 μm. 396 
 397 
Fig. 2. Mild pancreatitis in a 12-year-old male CKCS, characterised by one area of 398 
dissecting fibrosis (F) with lymphocytic infiltrate. H&E, bar: 300 μm. 399 
 400 
Fig. 3. Moderate pancreatitis in a 9-year-old male CKCS. Note multiple areas of 401 
dissecting fibrosis (arrow) with mononuclear inflammatory cells. H&E, bar: 300 μm. 402 
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 403 
Fig. 4. Marked chronic pancreatitis in a 13-year-old female CKCS, note extensive 404 
fibrosis (F) containing lymphocytes surrounding remaining pancreatic tissue (arrow). 405 
The fibrosis takes up >50% of the section. H&E, bar: 300 μm. 406 
 407 
Fig. 5. Pancreas of a 16-year-old female CKCS with end stage chronic pancreatitis. 408 
Most of the pancreatic tissue has been replaced collagenous stroma admixed with 409 
blood vessels (S). Only a very small amount of remaining acinar tissue is found 410 
(arrow). The pancreas was not grossly visible at post mortem. H&E, bar: 300 μm. 411 
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 412 
Fig. 6. An example of a kidney of a CKCS with glomerulonephritis and interstitial  413 
nephritis (arrows). H&E, bar: 300 μm. 414 
 415 
